/
J Exp Med
Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
- M. Serresi
- B. Siteur
- D. Hulsman
- C. Company
- M.J. Schmitt
- C. Lieftink
- B. Morris
- M. Cesaroni
- N. Proost
- R.L. Beijersbergen
- M. van Lohuizen
- G. Gargiulo